Immune Response Innovation: Chimeric Cell Therapy Breakthrough

The original patent addressed the challenge of immune response and inflammation in chimeric animals. However, its scope was limited to treating and preventing these responses in the context of chimeric animal development. This invention builds upon the original patent's core technology to expand its applicability to diverse biomedical fields, thereby solving the problem of limited translational potential.

The novelty of this invention lies in the application of the original patent's core technology to entirely new fields, thereby expanding its translational potential. The inventive step is the recognition that the chimeric animal models can be adapted to address specific biomedical challenges, and the development of novel methods and systems to achieve this.

Alternative embodiments of this invention could include the use of different types of stem cells, varying the timing and dosage of the treatment regimen, or incorporating additional components to enhance the chimeric animal model's functionality. Variations could also involve the development of chimeric animal models for other biomedical applications not explicitly mentioned in the new claims.

The commercial potential of this invention is vast, with potential applications in the fields of organ transplantation, cancer therapy, autoimmune disorder treatment, biomaterials, and tissue regeneration. The target market includes pharmaceutical and biotechnology companies, research institutions, and hospitals.